Distribution and therapeutic effect of intraarterially transferred tumor-infiltrating lymphocytes in hepatic malignancies. A preliminary report
Open Access
- 1 December 1991
- Vol. 68 (11) , 2391-2396
- https://doi.org/10.1002/1097-0142(19911201)68:11<2391::aid-cncr2820681110>3.0.co;2-7
Abstract
Indium‐111–labeled tumor‐infiltrating lymphocytes (111In‐TIL) were transferred as an intrahepatic arterial bolus to determine their in vivo distribution in patients with hepatic malignancies. In the in vitro culture system, TIL were expanded upon simultaneous stimulation by recombinant interleukin‐2 (rIL‐2) and immobilized anti‐CD3 monoclonal antibody. This double activation led not only to a larger cell yield, but also to a significantly more dominant subpopulation with CD4+ phenotype than occurred with activation by rIL‐2 alone. Accumulations of 111In‐TIL in the liver were identified by scintigraphy in all of three patients, corresponding to the tumor localization by computed tomography. Such accumulation had persisted for at least 48 hours after infusion. After intraarterial chemoimmunotherapy that included TIL, two of three patients achieved a partial therapeutic response. The authors conclude that their method of culture and transfer can facilitate the accumulation of TIL at tumor sites, which may augment the antitumor effects of adoptive immunotherapy. Cancer 68:2391–2396, 1991.Keywords
This publication has 13 references indexed in Scilit:
- TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCERThe Lancet, 1989
- Long-term growth of human T cell lines and clones on anti-CD3 antibody-treated tissue culture platesJournal of Immunological Methods, 1988
- Immunohistological analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesionsInternational Journal of Cancer, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Enhancement of murine lymphoma cell lysability by CTL and by LAK cells, after treatments with mitomycin C and with adriamycinInternational Journal of Immunopharmacology, 1986
- Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cellsCancer, 1984
- T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases.The Journal of Experimental Medicine, 1981
- Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapyThe American Journal of Medicine, 1981
- Primary Bioassay of Human Tumor Stem CellsScience, 1977